title: The impact of cognitive challenges in major depression: the role of the primary care physician.
abstract: Nearly 1 in 5 Americans will struggle with major depression in their lives; some will have recurring bouts. Recent psychiatric research has given new attention to the prevalence of cognitive deficits in major depression and the impact such deficits have on remission and overall life functioning. When depression is partially treated i.e., leaving residual symptoms, patients have higher rates of relapse and lower functional outcomes. Impaired cognitive functioning is a frequent residual symptom, persisting in about 45% of patients even when emotional symptoms have improved, and results in a disproportionate share of the functional impairment, particularly in the workplace. Patients with depression have disrupted circuitry in brain regions responsible for cognition and it is therefore important to screen depressed patients for cognitive as well as emotional symptoms. Cognitive dysfunction should be evaluated in every mood disordered patient with validated self-report scales such as the Patient Health Questionnaire-9 or the Beck Depression Inventory and objective measures of cognitive function are also very very useful. Two easily administered tests are the Trails B Test and the Digit Symbol Substitution Test. Each take less than two minutes and measure working memory, executive function, and processing speed and can track cognitive improvement in depressed patients. Treatment of cognitive dysfunction in major depression is complicated by the 'serotonin conundrum': SSRI's frequently do not treat to full remission, and can cause cognitive blunting-actually adding to cognitive problems. Based on recent data including results from a recently completed meta-analysis by McIntyre and colleagues, an evidence-based algorithm for treating cognitive symptoms in depression is presented. A hierarchy of antidepressants and augmentation strategies based on the best available evidence is discussed. In conclusion, cognitive symptoms in major depressive disorder have been recognized as a target of therapeutic improvement by the FDA and have become a focus of clinical importance.
authors: a Department of Psychiatry , Washington University School of Medicine , Saint Charles , MO , USA.
authors: Gregory
authors: G
authors: Mattingly
authors: b Midwest Research Group , Saint Charles , MO , USA.
authors: Richard H
authors: RH
authors: Anderson
authors: b Midwest Research Group , Saint Charles , MO , USA.
authors: Stephen G
authors: SG
authors: Mattingly
authors: b Midwest Research Group , Saint Charles , MO , USA.
authors: Elizabeth Q
authors: EQ
authors: Anderson
mesh_terms: D000928:Antidepressive Agents / Q000008:administration & dosage / Q000009:adverse effects; D003071:Cognition / Q000187:drug effects; D060825:Cognitive Dysfunction / Q000175:diagnosis / Q000209:etiology / Q000517:prevention & control; D003865:Major Depressive Disorder / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy; D006801:Humans; D009483:Neuropsychological Tests; D010819:Physician's Role; D058007:Physicians, Primary Care; D011569:Psychiatric Status Rating Scales
chemical_list: D000928:Antidepressive Agents
keywords: Depression; antidepressant; cognition; disability; duloxetine; residual symptoms; vortioxetine